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Endometrial cancer is the most common malig-nancy of the female genital tract in the world and the seventh most common cause of death 
from cancer in women in western Europe.1  The median 
age at diagnosis is the sixth decade, with abnormal uter-
ine bleeding at presentation in 90% of patients.2 While 
early-stage endometrial cancer typically responds well 
to standard therapies, low survival rates for advanced 
or recurrent disease result from limited and ineffective 
chemotherapy and hormonal treatment options. The 
American Cancer Society estimates that 15%, or 3 out 
of every 20 of women with stage IV endometrial cancer, 
will survive more than 5 years.3 
Cytotoxic chemotherapy is the mainstay of therapy 
for metastatic endometrial carcinoma. Many cytotoxic 
chemotherapy regimens have demonstrated activity, but 
response rates are modest with progression-free inter-
vals of approximately 4 to 6 months and median overall 
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BaCkgRounD anD oBjECtIvEs: the aim of this study was to evaluate the efficacy, safety and toxicity of 
docetaxel as first-line chemotherapy or in previously treated patients (one regimen) with recurrent or metastatic 
endometrial cancer.
DEsIgn anD sEttIng: Prospective phase ii study in patients referred to the Department of Clinical oncology 
and nuclear medicine, faculty of medicine, mansoura university, Egypt.
patIEnts anD MEthoDs: fifty patients with advanced or metastatic endometrial cancer were enrolled to 
receive docetaxel 70 mg/m2 administered intravenously on day 1 of a 3-week cycle. if patients responded well 
to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. 
therapy response was evaluated every 6 weeks.
REsuLts: of 50 patients with a median age of 60 years (range, 40-70 years) who entered the study, 17 patients 
(34%) had received one prior chemotherapy regimen. all patients were evaluable for efficacy, yielding an overall 
response rate of 34% (95% confidence interval, 14.8%–55.6%); complete response and partial response (Pr) 
were 4% and 30%, respectively. of 17 pretreated patients, 5 (29%) had a Pr. the median duration of response 
was 2 months. the median time-to-progression was 4 months and the median survival time was 18 months. the 
predominant toxicity was grade 3-4 neutropenia, occurring in 92% of the patients, although febrile neutropenia 
arose in 10% of the patients. Edema was mild and infrequent.
ConCLusIon: the study clearly demonstrated that docetaxel is active in the treatment of endometrial cancer. 
toxicity was manageable and predominantly hematologic.
survival in the range of 12 months.4 Many women with 
metastatic endometrial cancer are elderly and may have 
previously undergone pelvic radiation therapy, making 
them more susceptible to adverse effects of aggressive 
cytotoxic regimens.5
The taxanes, paclitaxel and docetaxel, are potent 
chemotherapeutic agents that block tubulin depoly-
merization, leading to the inhibition of microtubule dy-
namics, and have significant clinical efficacy for various 
solid tumours. Paclitaxel has been evaluated as an ac-
tive agent for endometrial cancer.6 However, preclinical 
data show that docetaxel has increased potency and an 
improved therapeutic index compared with paclitaxel7 
and its short 1-hour infusion time offers a substantial 
clinical advantage over the prolonged infusion dura-
tions required with paclitaxel. Docetaxel and paclitaxel 
also have substantially different toxicity profiles. In par-
ticular, docetaxel has a significantly lower incidence of 
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neurotoxicity in comparison to paclitaxel.8
There is limited reported experience with use of 
docetaxel in endometrial cancer, but objective clini-
cal activity has been demonstrated in a range (ap-
proximately 30% response rate) comparable with that 
documented with single-agent paclitaxel.9 The weekly 
administration of docetaxel in metastatic endometrial 
cancer has also been shown to be reasonably well toler-
ated and to result in objective clinical responses (20% 
response rate).10 In this study we evaluated the clinical 
efficacy and tolerability of docetaxel in patients with 
metastatic and recurrent endometrial cancer.
patIEnts anD MEthoDs
Patients were enrolled at the Clinical Oncology and 
Nuclear Medicine Department, Mansoura University 
Hospital. The eligiblility criteria for the patients in this 
study were as follows: age between 20 and 70 years, 
Eastern Cooperative Oncology Group (ECOG) per-
formance status 0-2 , primary lesion histologically 
confirmed to be endometrial carcinoma; International 
Federation of Gynecology and Obstetrics (FIGO) 
stage III, stage IV, or recurrent cancer; maximum mea-
surable diameter at computed tomography (CT) or 
magnetic resonance imaging at least 20 mm or a maxi-
mum measurable diameter at helical CT of at least 10 
mm. Patients were either chemotherapy-naive or had 
received one prior chemotherapy regimen for endome-
trial cancer, with 4 weeks between prior therapy and 
study treatment. Prior treatment with a taxane was 
not allowed. Adequate organ function was required 
for study entry: a neutrophil count greater than 2000/
mm3, platelet count greater than 100 000/mm3, serum 
bilirubin, SGOT, SGPT, serum creatinine within nor-
mal limit and normal electrocardiogram. No other his-
tory of active malignancy and no other serious medical 
disease. Written informed consent was obtained from 
all patients before registration.
Docetaxel 70 mg/m2 (Taxotere, Sanofi: Aventis) 
was infused over a 1-2 hour period. The treatment was 
repeated every 3 weeks unless there was documented 
disease progression or unacceptable toxicity. To pre-
vent docetaxel-related hypersensitivity or fluid reten-
tion, patients received premedication with six doses of 
corticosteroids—each equivalent to 50 mg of predniso-
lone—starting 12 hours before and ending 18 hours af-
ter the docetaxel infusion. Antiemetics were prescribed 
routinely before each cycle. If any adverse events listed 
below were seen during treatment in the previous cycle, 
the dose for the subsequent cycle was to be reduced by 
10 mg/m2 in the following instances: occurrence of fe-
brile neutropenia, grade 4 neutropenia persistent for at 
least 5 days, grade 4 thrombocytopenia, bleeding ten-
dency due to grade 3 thrombocytopenia, and platelet 
transfusion, or if a patient experienced any grade 3-4 
nonhematologic toxicities except nausea, vomiting, an-
orexia, fatigue, alopecia or hypersensitivity. In case of 
febrile grade 3 neutropenia or grade 4 neutropenia, the 
administration of G-CSF was permitted. Treatment 
was restarted when the neutrophil count was >1500/
mm3, platelet count >100 000/mm3, AST/ALT/ALP 
levels <2.5 times upper limit of nocturnal, and neu-
ropathy or edema <grade 1. 
The tumor response was assessed after two cycles 
of docetaxel according to the standard RECIST cri-
teria.11 Target lesions included all measurable lesions. 
Complete response (CR) was defined as the complete 
disappearance of all target and nontarget lesions, with 
no development of new disease. Partial response (PR) 
was defined as a reduction by >30% in the sum of the 
longest diameter of target lesions. CR or PR were con-
firmed by repeat assessments performed no less than 
4 weeks after the criteria for response were first met. 
The response rate was defined as a total of CR and PR. 
Progressive disease (PD) was defined as an increase by 
>20% in the sum of the longest diameter of all target 
lesions, or the appearance of one or more new lesions 
and/or unequivocal progression of existing, nontarget 
lesions. Stable disease (SD) was defined as neither suf-
ficient lesion shrinkage to qualify for a PR, nor suf-
ficient increase to qualify for PD. All tumors were 
radiographically assessed for response every 6 weeks. 
Toxicities were classified and evaluated by grade in ac-
cordance with the National Cancer Institute-Common 
Toxicity Criteria (Version 2).12
The primary end point was the response rate, and 
the secondary endpoints were the frequency of tox-
icities, and progression-free survival (PFS). Using this 
design, with 50 patients, we had a statistical power of 
80%, at a significance level of .05 to detect a 30% re-
sponse rate. The PFS was defined as the time from the 
first medication to the date of a PD event or death (due 
to endometrial cancer or study drugs). Overall survival 
(OS) was defined as time from diagnosis to death (in-
cluding deaths with or without recurrence) or last fol-
low up for those who were still alive. The PFS and OS 
rates were calculated by the Kaplan–Meier method. 
Statistical analysis was performed using a commercial-
ly available software package (SPSS for Windows 15; 
IBM Corp, Armonk, New York, United States).
REsuLts
From April 2008 to October 2011, 51 patients were 
enrolled. Data for one patient who did not receive treat-
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ment were deleted. Fifty patients were analyzed and 
evaluated for response, toxicity, and survival. Baseline 
characteristics of patients are listed in Table 1. The 
median age was 60 years, ranging from 40 to 70 years. 
The ECOG performance status at presentation was 0 
in 30 patients and 1 in 18 patients and only two patients 
(4%) had performance status 2. Recurrent disease was 
predominant (78% of patients). Grade II was the most 
common grade (40% of patients). Several patients had 
unfavorable histologic characteristics: adenosquamous 
features (3) and uterine papillary serous cancers (2). 
Most patients (90%) had undergone total abdominal 
hysterectomy and bilateral salpingo-ophorectomy, and 
one-half of patients had prior radiotherapy. Of those 
patients who received prior chemotherapy (17), 11 re-
ceived combination doxorubicin-platinum in combina-
tion, and 6 received platinum alone. 
The median number of docetaxel cycles received by 
patients was 6 (range, 2-10). Nine patients (18%) ex-
perienced dose reductions for the following reasons: 5 
patients experienced febrile neutropenia and 4 patients 
had nonhematologic toxicities: diarrhea (in 2 patients), 
neuropathy (in 2 patients). The most frequent reason 
for patients not receiving chemotherapy was patient 
refusal secondary to toxicity. Three patients terminated 
the study as a consequence of the following toxicities: 
grade 4 hypersensitivity reaction despite premedica-
tion with dexamethasone (2), infection associated with 
grade 3-4 neutropenia (2), and grade 3 edema with 
pleural effusion after six treatment cycles (1). 
Table 2 shows the assessment of response to treat-
ment. The overall response rate (ORR) was 17 of 50 
patients (34%, 95% CI, 14.8%–55.6%). Of 17 patients 
who had prior chemotherapy, 5 (29%) achieved a PR: 
3 had received doxorubicin-platinum and 2 had re-
ceived platinum alone. The histologic analysis revealed 
responses among the following tumor types: endome-
trioid adenocarcinoma (13 of 45 patients), squamous 
differentiated adenocarcinoma (2 of 3), papillary serous 
(2 of 2) and undifferentiated cancer (1 of 1). The me-
dian time for the onset of effect was 2.5 months (range, 
0.5–5.5) and the median duration of response was 2 
months (range, 1-5). The median follow-up time was 
18 months (range, 2-40 months) and median PFS was 
4 months (95% CI, 2-10 months) (Figure 1). Median 
survival time was 18 months (95% CI, 8-24 months).
In all, 50 patients were assessable for toxicity (Table 
3). The major adverse events were hematological toxic 
effects. Neutropenia was seen in nearly all patients, 46 
(92%) patients experienced grade 3 or 4 neutropenia, 
and five (10%) developed febrile neutropenia, infection 
associated with grade 3–4 neutropenia was reported 
Table 1.  baseline patient characteristics.
Characteristics No. of patients (%)
patients 50 (100)
age (y), Median (range) 60 (40-70)
eCOg performance status
   0 30 (60)
   1 18 (36)
   2 2 (4)
disease status
   Stage iii, iV 11(22)
   recurrent 39 (78)
Histology
   endometrioid 45 (90)
   adenocarcinoma with 
   squamous differentiated 3 (6)
   papillary serous 2 (4)
Tumor grade
   i 18 (36)
   ii 20 (40)
   iii 12 (24)
prior treatment
   Surgery 45 (90)
   radiotherapy 25 (50)
   Hormonal therapy 5 (10)
prior chemotherapy
   none 33 (66)
   doxorubicin and platinum 11 (22)
   platinum alone 6 (12)
in two patients. Nonhematologic toxicities included 
grade 3 or 4 anorexia and nausea and/or vomiting 
experienced by some patients (20% and 8%, respec-
tively). Other grade 3 gastrointestinal adverse events 
that occurred at high frequency were diarrhea and con-
stipation (4% and 12%, respectively). Grade 3 motor 
neuropathy occurred in one patient (2%), and sensory 
neuropathy occurred in two patients (4%). Three pa-
tients terminated the study as a consequence of the fol-
lowing toxicities: grade 4 hypersensitivity reaction de-
spite premedication with dexamethasone (2), infection 
associated with grade 3–4 neutropenia (2), and grade 
3 edema with pleural effusion after six treatment cycles 
(1). All three patients recovered after receiving recom-
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mended medical treatment. There were no treatment-
related deaths.
DIsCussIon
Endometrial cancer is the most common gynecologic 
cancer.13 The mainstay of treatment of recurrent and 
metastatic endometrial cancer remains systemic ther-
apy in the form of hormonal therapy or cytotoxic che-
motherapy.5 There have been a few prospective trials 
designed to study the feasibility and efficacy of system-
ic chemotherapy in advanced cases of endometrial can-
cer.14 Patients with low-grade disease with estrogen re-
ceptor (ER)-positive and progesterone receptor (PR)-
positive carcinoma tend to respond as well to hormonal 
therapy as to cytotoxic chemotherapy, with fewer side 
effects. Hormonal therapy may also be prioritized in 
Table 2. response (reCiST criteria ) to docetaxel. 
Response
Patients received prior 
chemotherapy (17 patients )
Patients did not receive prior 
chemotherapy (33 patients)
Total
(50 patients)
No. of patients     % No. of patients     % No. of patients    %
Complete 
response 0               0 2                           .06 2 .4
partial response 5                          29 10                         30 15 30
Stable disease 6                         35 9             27 15 30
progressive 
disease 6                                 35 12           37 18 36
Overall 
response rate 5 29 12 36 17 34
Figure 1. Kaplan-Meier curve of estimated progression-free 
survival.
patients with poor performance status and/or multiple 
medical comorbidities. Cytotoxic chemotherapy may 
be more appropriate as initial therapy for younger pa-
tients with high grade disease.5 Cisplatin plus doxoru-
bicin was the standard of care for many years but the 
response has been mostly only partial with short dura-
tion.15 Because of the low benefit of prior treatments, 
trials with new chemotherapeutic agents are strongly 
needed. Taxanes have shown activity in this setting 
previously, with paclitaxel demonstrating overall re-
sponse rates of 27% to 37% when used as a single agent 
in endometrial cancer.6,16,17
 In our study, the ORR was 34%, the CR 4%, the 
PR 30% and SD was presen in 30% while 36% had PD. 
The median PFS was 4 months and median survival 
18 months. Of 17 pretreated patients, 5 (29%) had a 
PR, suggesting that docetaxel is also active as second-
line therapy. Katsumata et al,9 in Japan (in 2005), had 
similar findings in their trial of docetaxel in 32 patients 
with advanced and metastatic endometrial cancer with 
an ORR of 31% (11 patients); CR and PR were 3% 
and 28%, respectively. Of 13 pretreated patients, 3 
(23%) had a PR. The median time-to-progression was 
3.9 months. Median survival time was 17.8 months.
Combination chemotherapy with paclitaxel and 
carboplatin or cisplatin has resulted in response rates 
of 50% to 56%.18-20 However, a GOG phase III trial 
in endometrial cancer compared cisplatin plus doxo-
rubicin to doxorubicin, cisplatin, and paclitaxel with 
G-CSF support. The three-drug arm produced more 
objective responses than the two-drug arm (57% vs 
34%, P<.01). PFS was extended to 8.3 months com-
pared with 5.3 months in the control arm (P<.01); 
and overall survival reached a median of 15.3 months 
compared with 12.3 months (P<.037) . However, more 
grade 3 neuropathy (12% vs 1%) and congestive heart 
failure were observed with three-drug combination 
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Table 3. adverse effects.
        Toxicity
 Grade 3   Grade   4  Grade 3-4    
No. of 
patients         %
No. of 
patients %
No. of 
patients %
Hematologic
   Hemoglobin 2                        4 1 2 3 6
   WbC 15                      30 10 20 25 50
   platelets 0                                 0 0                  0 0 0
   neutrophils 16                       32 30 60 46 92
Nonhematologic
   Fatigue 4 8 0 0 4 8
   Febrile neutropenia 1 2 4 8 5 10
   infection 0 0 2 4 2 4
   allergic reaction 0 0 2 4 2 4
   nail changes 0 0 0 0 0 0
   Oedema 1 3 0 0 1 2
   neuropathy-motor 1 2 0 0 1 2
   neuropathy-sensory 2 4 0 0 2 4
   rash/desquamation 1 2 0 0 1 2
   nausea and/or 
   vomiting 3 6 1 2 4 8
   Constpation 6 12 0 0 6 12
   diarrhea 2 6 0 0 2 4
   Stomatitis 1 2 0 0 1 2
   anorexia 10 20 0 0 10 20
than with two-drug combination.15 As seen in previous 
trials, increasing efficacy with more chemotherapy also 
led to increasing toxicity; patients receiving the three-
drug combination were more likely to suffer congestive 
heart failure and grade 3 and 4 neurotoxicity. In view of 
this imbalance between efficacy and toxicity, the three-
drug combination has not been accepted as the stan-
dard chemotherapy regimen in routine clinical prac-
tice. Attarian et al assessed carboplatin plus paclitaxel 
in patients with advanced, locoregional recurrence and 
metastatic endometrial cancer; the ORR was 54% (16 
of 30), with a CR in 13% and PR in 40%. The median 
PFS was 8.2 months. The 6-month OS was 80%.21 In 
a previous trial of combination chemotherapy, ORR 
and PFS were superior to our results as we used single 
agent, but we reported low rates of serious toxicities 
and better OS. These toxicities were manageable and 
predominantly hematologic. 
Docetaxel has a toxicity profile that is different from 
paclitaxel. In particular, neurotoxicity occurs at a low 
incidence with docetaxel. In current study , 92% of pa-
tients developed neutropenia (grade 3 and 4), 10% had 
febrile neutropenia, only one patient developed grade 3 
motor neuropathy and 4% developed grade 3 sensory 
neuropathy and recovered in several weeks. Only one 
patient developed pleural effusion and grade 3 edema 
since the routine premedication with corticosteroids 
was not applied. 
In conclusion, this prospective phase II trial, al-
though relatively small in sample size, clearly dem-
onstrated that docetaxel is active in the treatment of 
endometrial cancer. Toxicity was manageable and 
predominantly haematologic. The exploration of the 
efficacy of docetaxel combinations for the treatment 
of endometrial cancer is of great interest and will be 
initiated.
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